Drug manufacturer Eli Lilly announced on Thursday that an unusual experiment aimed at preventing nursing home staff and residents from contracting the coronavirus has been successful.
According to the preliminary results of a study conducted in collaboration with the National Institutes of National Institute, a drug containing monoclonal antibodies-a viral combat agent grown in a laboratory-can prevent residents who are exposed to the virus even Symptoms of infection in the most vulnerable elderly. health.
The researchers found that compared with the residents who used the placebo, the infections of the residents who used the drug were reduced by 80%, and the reduction among the staff was 60%. This result is statistically very strong.
The study included 965 nursing home participants: 666 staff and 299 residents. (The company had hoped that more residents would participate, but it proved difficult to recruit them; many had dementia, while others were reluctant to receive intravenous drugs.)
Four of the study participants died of Covid-19. All of them were residents of nursing homes, and they received placebos instead of drugs.
The pannibizumab drug has received emergency use permission from the US Food and Drug Administration, allowing Eli Lilly to provide it to symptomatic patients in the early stages of infection.
But this study asked whether the drug could stop the infection before it started. This is an unusual experiment: in a truck equipped with a mobile laboratory, medical staff rushed to a nursing home as soon as they found an infection there. After the workers arrived, a temporary infusion center was established to manage drugs.
The research ended this weekend with an emergency meeting of the Data Security and Surveillance Committee, an independent group responsible for monitoring the results received. The data is strong and convincing enough to stop the placebo.
Although the exact order of vaccinators may vary from state to state, most people may put medical workers and residents of long-term care facilities first. If you want to know how to make this decision, then this article will help you.
Only when the entire society is protected against the coronavirus can life return to normal. Once the country/region has approved the vaccine, they can only vaccinate at most a few percent of its citizens in the first few months. Most people who have not been vaccinated are still vulnerable to infection. More and more coronavirus vaccines show strong disease prevention capabilities. But it is also possible for people to spread the virus without even knowing that they are infected because they will only experience mild symptoms or no symptoms at all. Scientists do not yet know whether these vaccines can also stop the spread of coronavirus. Therefore, for the time being, even people who have been vaccinated need to wear masks to avoid indoor crowds. Once enough people are vaccinated, it will be difficult for the coronavirus to find people who are susceptible to infection. Depending on how quickly we achieve our goals as a society, by the fall of 2021, life may begin to approach normal levels.
Yes, but not forever. Two vaccines may be approved this month, and they will obviously protect people from Covid-19. However, the clinical trials that provide these results are not designed to determine whether the vaccinated people can still transmit the coronavirus without symptoms. That is still possible. We know that people who are naturally infected by the coronavirus can spread it without any cough or other symptoms. With the introduction of the vaccine, researchers will focus on this issue. At the same time, even vaccinated people need to see themselves as possible spreaders.
Like other typical vaccines, Pfizer and BioNTech vaccines can also be shot in one shot. The injection is not any different from the injection you received before. Thousands of people have been vaccinated, and none of them have reported any serious health problems. But some of them experience brief discomfort, including pain that usually lasts a day and flu-like symptoms. People may need to plan a day off or a day off school after the second shot. Although these experiences are not pleasant, they are a good sign: they are the result of your own immune system encountering a vaccine and producing an effective response that will provide lasting immunity.
Not possible. Vaccines from Moderna and Pfizer use genetic molecules to activate the immune system. This molecule is called mRNA and will eventually be destroyed by the body. The mRNA is packaged in an oily bubble that can fuse with the cell, allowing the molecule to slide into the cell. Cells use mRNA to make proteins from coronaviruses to stimulate the immune system. At any time, each of our cells may contain thousands of mRNA molecules, and they will produce these molecules to make their own proteins. After these proteins are made, our cells use special enzymes to chop up mRNA. The mRNA molecules made by our cells can only survive for a few minutes. The mRNA in the vaccine is designed to withstand cellular enzymes for a longer period of time, so that the cells can produce additional viral proteins and promote a stronger immune response. However, mRNA can only last a few days before it can be destroyed.
Dr. Myron Cohen, a professor of medicine at the University of North Carolina at Chapel Hill and the lead researcher who helped design and implement the study, said: “When I saw the results table, my jaw dropped.”
Although the research is over, Eli Lilly’s chief scientific officer, Dr. Daniel Kokowski, said that once an outbreak is discovered, the company will continue to rush to nursing homes in its research network. He said: “Everyone will get drugs.”
The experts who did not participate in the study were enthusiastic, but emphasized that they have not yet seen the complete data. Dr. Ofer Levy, director of the Precision Vaccine Program at Boston Children’s Hospital, said: “I only see the positive side here.” “This is a victory.”
Dr. Catherine Neuzier, director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine, was also encouraged.
She said: “The mortality rate is significant,” she added, adding that the drug should be used more widely to prevent and treat Covid-19, “especially among people such as nursing home residents, who have a high mortality rate. The vaccine response may not be ideal.”
Of course, vaccines can also protect people from viral infections. Nursing home staff and residents are among the priority groups for injection. However, the supply is insufficient, and many nursing home staff who are worried about the vaccine refuse to obtain the vaccine.
Dr. Sriratta Edupuangiti, a vaccine researcher at Emory University in Atlanta, said that after vaccination, it may take up to six weeks for the human body to produce enough antibodies to provide maximum protection.
She said that monoclonal antibody therapy can provide almost the same protection immediately, although it lasts less than the protection provided by the vaccine.
Dr. Skovronsky said that Eli Lilly plans to contact the FDA regarding the emergency use of the drug to authorize the drug to be used to prevent infection in vulnerable elderly populations, especially in nursing homes or long-term care facilities.